Skylight Investment

Sky Light Invest, based in Dubai, is an investment firm offering private equity, mezzanine financing, and venture capital. It targets both traditional industries like green metals, energy, and transportation assets, and technology sectors such as FinTech, E-commerce, EdTech, data analytics, and Blockchain. Beyond capital, it provides corporate development advisory to its portfolio.

CEO Anton Gazizov, with over two decades in private equity and venture capital, leads Sky Light Invest. His background includes Deutsche Bank, Goldman Sachs, and QVT, with education from Cambridge and London Business School. The firm originated from the conviction that innovative companies flourish with robust financial and strategic guidance.

The firm backs ambitious entrepreneurs and growing companies seeking strategic capital and partnership. Sky Light Invest's vision empowers these businesses, ensuring promising ideas achieve significant growth and exceptional returns. It proactively collaborates with founders, guiding portfolio companies to realize their full potential.

High-Level Overview

Skylight Investment is a venture capital firm based in Boston, Massachusetts (with references to Brookline), founded in 2016, that invests in early-stage startups with disruptive technologies.[1][2][3] Its mission centers on backing companies in sectors like technology, Internet of Things (IoT), SaaS, FinTech, Artificial Intelligence & Machine Learning, Life Sciences, Robotics and Drones, biotechnology, hardware, blockchain, transportation, tourism, and novel materials, with a portfolio skewed toward therapeutics, medical devices, wellness, and personal health in the US.[1][2][3][5] The firm typically targets startups valued at $5-10 million, invests in deals of $5-10 million, and participates in fewer than 2 deals per year, with peak activity in 2018 and notable investments like Tivic Health.[2] Its investment philosophy emphasizes excellent teams and disruptive tech in early stages (seed, early VC, later VC), contributing to the startup ecosystem through selective support for 2-3 year-old companies, primarily in the US.[1][2][3]

Origin Story

Skylight Investment was established in 2016 as a VC fund in North America, specifically in the United States, with its main office in Brookline near Boston.[2] Limited public details exist on key partners or founders, but the firm quickly focused on early-stage investments in high-tech sectors, aligning its location with its primary investment geography in the US.[2] Its evolution shows consistent but low-volume activity—around 8 total investments, 1 round per year on average, and a follow-on index of 0.25—with heightened deal flow in 2019 and peak in 2018, including portfolio companies like Tivic Health in wellness and CRM-related areas.[2] This trajectory reflects a deliberate, niche approach rather than rapid expansion.

Core Differentiators

• Early-Stage Focus on Disruptive Tech: Targets seed, early, and later-stage VC in startups aged 2-3 years with valuations of $5-10M, prioritizing robotics, biotech, AI, blockchain, hardware, and novel materials.[1][2][3][5]
• Selective Deal Flow: Averages under 2 investments yearly across 8 total deals, enabling deep involvement without overextension; no lead investments noted.[2]
• Sector Expertise: Strong in health-related areas (therapeutics, medical devices, wellness: 3-4 investments each) and emerging tech like IoT, FinTech, and Life Sciences, all US-based.[1][2]
• Track Record: Portfolio includes Tivic Health; emphasizes teams with "excellent" potential for disruption, though specific operating support or network details are not publicly detailed.[2][3]

Role in the Broader Tech Landscape

Skylight Investment rides trends in AI, robotics, biotech, and blockchain, sectors experiencing explosive growth due to advancements in automation, personalized medicine, and decentralized finance.[1][3][5] Its timing since 2016 aligns with the post-2015 AI boom and biotech funding surge, amplified by market forces like increased VC inflows into US health tech (e.g., therapeutics and medical devices comprising much of its portfolio).[2] By selectively funding early-stage disruptors, it influences the ecosystem through capital for 2-3 year-old startups, helping bridge seed to growth amid competition from larger funds; its US focus leverages America's dominance in these fields.[2]

Quick Take & Future Outlook

Skylight Investment's low-volume, high-conviction model positions it well for continued niche impact in AI-biotech intersections and Web3 hardware, especially as 2025 trends like AI-driven drug discovery and robotics scale.[1][2][5] Upcoming deals may rise with maturing portfolios (e.g., follow-ons at 0.25 index), shaped by regulatory tailwinds in FinTech/blockchain and US innovation hubs.[2] Its influence could evolve toward more therapeutics/wellness plays, amplifying early-stage momentum in a consolidating VC landscape—echoing its founding bet on disruptive teams to sustain long-term ecosystem contributions.[2][3]